How to buy Cochlear shares
Own Cochlear shares in just a few minutes.
Cochlear Limited is a medical devices business based in Australia. Cochlear shares (COH) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Cochlear has a trailing 12-month revenue of around $1.3 billion.
How to buy shares in Cochlear
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Cochlear. Find the share by name or ticker symbol: COH. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cochlear reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $N/A, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Cochlear. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Cochlear key stats
- Compare share trading platforms
- Is Cochlear stock a buy or sell?
- Cochlear performance over time
- Is Cochlear suitable for ethical investing?
- Are Cochlear shares over-valued?
- Cochlear's financials
- How volatile are Cochlear shares?
- Does Cochlear pay a dividend?
- Other common questions
Cochlear share priceUse our graph to track the performance of COH stocks over time.
Cochlear shares at a glance
|52-week range||AUDA$154.6 - AUDA$254.4|
|50-day moving average||AUDA$196.4286|
|200-day moving average||AUDA$190.5122|
|Dividend yield||AUDA$3.35 (0.94%)|
|Earnings per share (TTM)||AUDA$5.294|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Cochlear stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Cochlear under- or over-valued?
Valuing Cochlear stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cochlear's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cochlear's P/E ratio
Cochlear's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Cochlear shares trade at around 48x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cochlear's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $259.6 million.
The EBITDA is a measure of a Cochlear's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.3 billion|
|Operating margin TTM||16.76%|
|Gross profit TTM||$964.7 million|
|Return on assets TTM||6.99%|
|Return on equity TTM||-22.4%|
|Market capitalisation||$13.3 billion|
TTM: trailing 12 months
Cochlear's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Cochlear.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Cochlear's total ESG risk score
Total ESG risk: 25.27
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Cochlear's overall score of 25.27 (as at 07/31/2020) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Cochlear is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Cochlear's environmental score
Environmental score: 3.73/100
Cochlear's environmental score of 3.73 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Cochlear's social score
Social score: 12.87/100
Cochlear's social score of 12.87 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Cochlear's governance score
Governance score: 7.18/100
Cochlear's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Cochlear is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Cochlear's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Cochlear scored a 1 out of 5 for controversy – the highest score possible, reflecting that Cochlear has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||25.27|
|Total ESG percentile||45.4|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||1|
Cochlear share dividends
Dividend payout ratio: 62.33% of net profits
Recently Cochlear has paid out, on average, around 62.33% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.94% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Cochlear shareholders could enjoy a 0.94% return on their shares, in the form of dividend payments. In Cochlear's case, that would currently equate to about A$3.35 per share.
Cochlear's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 23 March 2020 (the "ex-dividend date").
Cochlear share price volatility
Over the last 12 months, Cochlear's shares have ranged in value from as little as $154.6 up to $254.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cochlear's is 0.4849. This would suggest that Cochlear's shares are less volatile than average (for this exchange).
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Frequently asked questions
Ask an Expert